Trial Radar AI | ||
|---|---|---|
Clinical Trial NCT05362058 (QWINT-2) for Diabetes, Type 2 Diabetes is completed. See the Trial Radar Card View and AI discovery tools for all the details. Or ask anything here. | ||
One study matched filter criteria
Card View
Back to Search
Eli Lilly and CompanyA Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time (QWINT-2) Phase 3 928
Clinical Trial NCT05362058 (QWINT-2) was designed to study Treatment for Diabetes, Type 2 Diabetes. This was a Phase 3 interventional study that is now completed. The study started on 3 June 2022, with plans to enroll 928 participants. Led by Eli Lilly and Company, the expected completion date was 10 April 2024. The latest data from ClinicalTrials.gov was last updated on 16 May 2025.
Brief Summary
The purpose of this study is to determine the effect and safety of insulin efsitora alfa (LY3209590) compared to degludec in adult participants with type 2 diabetes who are starting basal insulin for the first time. The study consists of a 1-week screening period, a 2-week lead-in period, a 52-week treatment period, and a 5-week safety follow-up period. The study will last up to 60 weeks.
Official Title
A Phase 3, Parallel-Design, Open-Label, Randomized Control Study to Evaluate the Efficacy and Safety of LY3209590 as a Weekly Basal Insulin Compared to Insulin Degludec in Insulin Naïve Adults With Type 2 Diabetes
Conditions
DiabetesType 2 DiabetesPublications
Scientific articles and research papers published about this clinical trial:Other Study IDs
- QWINT-2
- 18262
- I8H-MC-BDCX (Other Identifier) (Eli Lilly and Company)
- 2021-005891-21 (EudraCT Number)
NCT ID Number
Start Date (Actual)
2022-06-03
Last Update Posted
2025-05-16
Completion Date (Estimated)
2024-04-10
Enrollment (Estimated)
928
Study Type
Interventional
PHASE
Phase 3
Status
Completed
Primary Purpose
Treatment
Design Allocation
Randomized
Interventional Model
Parallel
Masking
None (Open Label)
Arms / Interventions
| Participant Group/Arm | Intervention/Treatment |
|---|---|
Experimental500 U/mL - Insulin Efsitora Alfa * Participants received 500 units per milliliter (U/mL) of insulin efsitora alfa administered subcutaneously (SC) once weekly (QW) over a 52-week treatment period, followed by a 5-week safety follow-up period.
* Participants continued their protocol-specified stable therapy with non-insulin antihyperglycemic medications throughout the study, at the discretion of the investigator. | Insulin Efsitora Alfa Administered SC |
Active Comparator100 U/mL - Insulin Degludec * Participants received 100 U/mL insulin degludec administered SC once daily (QD) over a 52-week treatment period, followed by a 5-week safety follow-up period.
* Participants continued their protocol-specified stable therapy with non-insulin antihyperglycemic medications throughout the study, at the discretion of the investigator. | Insulin Degludec Administered SC |
Primary Outcome Measures
Secondary Outcome Measures
| Outcome Measure | Measure Description | Time Frame |
|---|---|---|
Change From Baseline in HbA1c at Week 52 [Noninferiority Analysis] | * HbA1c is the glycosylated fraction of hemoglobin A. It is measured to identify average plasma glucose concentration over prolonged periods of time.
* Least Squares (LS) mean was determined using Analysis of Covariance (ANCOVA) model with Baseline + Country + GLP-1 RA Use at Randomization Flag + SU Use at Randomization Flag + Treatment (Type III sum of squares) as variables. Missing data at Week 52 were imputed by return-to-baseline multiple imputations approach. | Baseline, Week 52 |
| Outcome Measure | Measure Description | Time Frame |
|---|---|---|
Change From Baseline in HbA1c at Week 52 in Participants Using GLP-1 Receptor Agonists [Noninferiority Analysis] | * HbA1c is the glycosylated fraction of hemoglobin A. It is measured to identify average plasma glucose concentration over prolonged periods of time.
* LS mean was determined using ANCOVA model with Baseline + Country + SU Use at Randomization Flag + Treatment (Type III sum of squares) as variables. Missing data at Week 52 were imputed by return-to-baseline multiple imputations approach. | Baseline, Week 52 |
Change From Baseline in HbA1c at Week 52 in Participants Not Using GLP-1 Receptor Agonists [Noninferiority Analysis] | * HbA1c is the glycosylated fraction of hemoglobin A. It is measured to identify average plasma glucose concentration over prolonged periods of time.
* LS mean was determined using ANCOVA model with Baseline + Country + SU Use at Randomization Flag + Treatment (Type III sum of squares) as variables. Missing data at Week 52 were imputed by return-to-baseline multiple imputations approach. | Baseline, Week 52 |
Change From Baseline in HbA1c at Week 52 [Superiority Analysis] | * HbA1c is the glycosylated fraction of hemoglobin A. It is measured to identify average plasma glucose concentration over prolonged periods of time.
* LS mean was determined using ANCOVA model with Baseline + Country + GLP-1 RA Use at Randomization Flag + SU Use at Randomization Flag + Treatment (Type III sum of squares) as variables. Missing data at Week 52 were imputed by return-to-baseline multiple imputations approach. | Baseline, Week 52 |
Percentage of Time in the Blood Glucose Range Between 70 and 180 mg/dL [3.9 and 10.0 mmol/L] - Week 48 to Week 52 | * Percentage of time spent within the blood glucose range of 70 to 180 milligrams per deciliter (mg/dL) \[3.9 to 10.0 millimoles per liter (mmol/L)\], as measured during the continuous glucose monitoring (CGM) session over a 24-hour period, from Week 48 to Week 52.
* LS mean was determined using ANCOVA model with Baseline + Country + HbA1c Stratum at Baseline + GLP-1 RA Use at Randomization + SU Use at Randomization + Treatment (Type III sum of squares) as variables. Missing data at baseline were imputed using multiple imputation under the assumption of missing at random, while missing data at Week 48-52 were imputed using a return-to-baseline multiple imputation approach. | Week 48 to Week 52 |
Change From Baseline in HbA1c at Week 26 [Superiority Analysis] | * HbA1c is the glycosylated fraction of hemoglobin A. It is measured to identify average plasma glucose concentration over prolonged periods of time.
* LS mean was determined using ANCOVA model with Baseline + Country + GLP-1 RA Use at Randomization Flag + SU Use at Randomization Flag + Treatment (Type III sum of squares) as variables. Missing data at Week 26 were imputed by return-to-baseline multiple imputations approach. | Baseline, Week 26 |
Percentage of Time in the Blood Glucose Range Between 70 and 180 mg/dL [3.9 and 10.0 mmol/L] - Week 22 to Week 26 | * Percentage of time spent within the blood glucose range of 70 to 180 mg/dL (3.9 to 10.0 mmol/L), as measured during the CGM session over a 24-hour period, from Week 22 to Week 26.
* LS mean was determined using ANCOVA model with Baseline + Country + HbA1c Stratum at Baseline + GLP-1 RA Use at Randomization + SU Use at Randomization + Treatment (Type III sum of squares) as variables. Missing data at baseline were imputed using multiple imputation under the assumption of missing at random, while missing data at Week 22-26 were imputed using a return-to-baseline multiple imputation approach. | Week 22 to Week 26 |
Change From Baseline in Fasting Blood Glucose (FBG) | Change from baseline in fasting blood glucose measured by self-monitoring blood glucose (SMBG). | Baseline, Week 26, Week 52 |
Glucose Variability | * Glucose variability measured as coefficient of variation (CV) for blood glucose during the CGM session over a 24-hour period, between Week 22 to Week 26 and Week 48 to Week 52 was reported.
* LS mean was determined using Mixed Model Repeated Measures (MMRM) model with Baseline + Country +HbA1c Stratum at Baseline + GLP-1 RA Use at Randomization Flag + SU Use at Randomization Flag + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables. | Week 22 to Week 26 and Week 48 to Week 52 |
Basal Insulin Dose | * The insulin dose was calculated based on the participant's entry of daily or weekly insulin doses in an electronic diary. The average weekly basal insulin dose at Week 26 and Week 52 was reported.
* LS mean was determined using MMRM model with Country + HbA1c Stratum at Baseline + GLP-1 RA Use at Randomization Flag + SU Use at Randomization Flag + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables. | Week 26 and Week 52 |
Hypoglycemia Event Rate | * A hypoglycemic event with blood glucose (BG) levels of less than (\<) 54 mg/dL (3.0 mmol/L) \[Level 2\] or Severe Hypoglycemia \[Level 3\] was reported. A severe hypoglycemic event was characterized by altered mental or physical status, requiring the assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions for the treatment of hypoglycemia.
* Group mean was reported and determined by Negative binomial model using Number of episodes = HbA1c at Baseline (%) + Treatment, with log (exposure in days/365.25) as an offset variable. | Baseline up to Week 52 |
Nocturnal Hypoglycemia Event Rate | * The event rate of participant-reported clinically significant nocturnal hypoglycemia (defined as blood glucose level \<54 mg/dL (3.0 mmol/L) or severe hypoglycemia and occurs at night and presumably during sleep between midnight and 6:00 AM), measured during treatment phase up to week 52.
* Group mean was reported and determined by Negative binomial model using Number of episodes = HbA1c at Baseline (%) + Treatment, with log (exposure in days/365.25) as an offset variable. | Baseline up to Week 52 |
Change From Baseline in Body Weight | Change from baseline in body weight was reported. LS mean was determined by MMRM model with Baseline + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables. | Baseline, Week 26, Week 52 |
Percentage of Time in Hypoglycemia Range With Blood Glucose <70 mg/dL (3.9 mmol/L) | * Percentage of time spent in the hypoglycemia range with blood glucose \<70 mg/dL (3.9 mmol/L), as measured during the CGM session over a 24-hour period from Week 8 to Week 12, Week 22 to Week 26, and Week 48 to Week 52 was reported.
* LS mean was determined using MMRM model with Baseline + HbA1c Stratum at Baseline + Country + GLP-1 RA Use at Randomization Flag + SU Use at Randomization Flag + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables. | Week 8 to Week 12, Week 22 to Week 26 and Week 48 to Week 52 |
Percentage of Time in Hypoglycemia Range With Blood Glucose <54 mg/dL (3.0 mmol/L) | * Percentage of time spent in the hypoglycemia range with blood glucose \< 54 mg/dL (3.0 mmol/L), as measured during the CGM session over a 24-hour period from Week 8 to Week 12, Week 22 to Week 26, and Week 48 to Week 52, was reported.
* LS mean was determined using MMRM model with Baseline + HbA1c Stratum at Baseline + Country + GLP-1 RA Use at Randomization Flag + SU Use at Randomization Flag + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables. | Week 8 to Week 12, Week 22 to Week 26 and Week 48 to Week 52 |
Percentage of Time in Hyperglycemia Range With Blood Glucose >180 mg/dL (10.0 mmol/L) | * Percentage of time spent in the hyperglycemia range with blood glucose greater than (\>) 180 mg/dL (10.0 mmol/L), as measured during the CGM session over a 24-hour period from Week 8 to Week 12, Week 22 to Week 26, and Week 48 to Week 52 was reported.
* LS mean was determined using MMRM model with Baseline + HbA1c Stratum at Baseline + Country + GLP-1 RA Use at Randomization Flag + SU Use at Randomization Flag + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables. | Week 8 to Week 12, Week 22 to Week 26 and Week 48 to Week 52 |
Change From Baseline in Treatment-Related Impact Measures for Diabetes (TRIM-D) -Total Score at Week 26 and Week 52 | * The TRIM-D is a participant-reported measure designed to assess the impact of diabetes treatment on individuals' functioning and well-being across different diabetes treatments. The questionnaire includes 28 items grouped into 5 sub-domains: treatment burden, daily life, diabetes management, compliance, and psychological health. Each item is assessed on a 5-point scale, with higher scores indicating better health status. All items were summed to obtain a total raw score, which was transformed to a scale of 0 to 100 to obtain a total score. The total score range is 0-100, with a higher total score indicating better overall health and well-being, while a lower total score indicates worse health or well-being.
* LS mean was determined using MMRM model with Baseline + Country + HbA1c Stratum at Baseline + GLP-1 RA Use at Randomization Flag + SU Use at Randomization Flag + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables. | Baseline, Week 26, Week 52 |
Change From Baseline in Short Form-36 Health Survey Version 2 (SF-36v2) Acute Form (Physical-Component and Mental-Component) Scores at Week 26 and Week 52 | The SF-36v2 is a participant-reported measure designed to assess health status using 36 items across 8 domains: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional, and Mental Health. Each domain is scored individually, and information from these 8 domains is further aggregated into 2 health component summary scores, the Physical Component Summary and Mental Component Summary. Scoring of each domain and both summary scores are norm based and presented in the form of T-scores, with a mean of 50 and a standard deviation of 10. Higher scores indicate better levels of function and/or better health. Range cannot be specified in norm-based scores. | Baseline, Week 26, Week 52 |
Change From Baseline in EuroQuality of Life (EuroQol) - 5 Dimensions-5 Levels (EQ-5D-5L) Health State Index and EQ Visual Analog Scale (VAS) Scores at Week 26 and Week 52 | The EQ-5D-5L is a multidimensional, health-related, quality-of-life instrument. It includes 5 dimensions of health (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) that are assessed at 5 levels of response (no problems, slight problems, moderate problems, severe problems, and unable to perform or extreme problems). The scores in the 5 dimensions were summarized into a health state index score. A single health-state index value was derived, which ranges from less than 0 (health state equivalent to death, negative values are valued as worse than death) to 1 (perfect health). The EQ VAS rates the participants' perceived health from 0 (the worst imaginable health) to 100 (the best imaginable health). This score provides a composite picture of the respondent's health status. | Baseline, Week 26, Week 52 |
Eligibility Criteria
Eligible Ages
Adult, Older Adult
Minimum Age
18 Years
Eligible Sexes
All
Have diagnosis of Type 2 diabetes (T2D) according to the World Health Organization Criteria
Have an Hemoglobin A1c (HbA1c) of 7.0 percent (%) - 10.5% inclusive, at screening
Are on a stable treatment with 1 to 3 antihyperglycemic medication for at least 3 months prior to screening and willing to continue the stable treatment for the duration of the study
These antihyperglycemic medications are accepted in the study
- dipeptidyl peptidase-4 (DPP-4) inhibitors
- sodium-glucose cotransporter 2 (SGLT2) inhibitors
- biguanides, such as metformin
- alpha-glucosidase inhibitors
- glucagon-like peptide-1 (GLP-1) receptor agonists, oral or injectable
- Sulfonylureas, or
- Thiazolidinediones.
Are insulin naïve.
Exceptions:
short-term insulin treatment for a maximum of 14 days, prior to screening, and prior insulin treatment for gestational diabetes
- Have a body mass index of less than or equal to (≤) 45 kilogram/square meter (kg/m²).
Have a diagnosis of Type 1 diabetes (T1D), latent autoimmune diabetes, or a specific type of diabetes other than T2D, for example, monogenic diabetes, diseases of the exocrine pancreas, or drug-induced or chemical-induced diabetes.
Have a history of greater than (>) 1 episode of ketoacidosis or hyperosmolar state or coma requiring hospitalization within 6 months prior to screening. Have had severe hypoglycemia episodes within 6 months prior to screening. Have a history of renal transplantation, are currently receiving renal dialysis, or have an estimated glomerular filtration rate.
Have known hemoglobinopathy, hemolytic anemia or sickle cell anemia, or any other traits of hemoglobin abnormalities known to interfere with the measurement of HbA1c.
Have had New York Heart Association Class IV heart failure or any of these cardiovascular conditions within 3 months prior to screening
- Acute myocardial infarction
- Cerebrovascular accident (stroke), or
- Coronary bypass surgery.
- Have had gastric bypass (bariatric) surgery, restrictive bariatric surgery, for example Lap-Band, or sleeve gastrectomy within 1 year prior to screening
- Have had significant weight gain or loss within 3 months prior to screening, for example, greater than or equal to (≥) 5%.
Eli Lilly and Company362 active studies to exploreNo contact data.
113 Study Locations in 11 Countries
California
Neighborhood Healthcare Institute of Health, Escondido, California, 92025, United States
Valley Research, Fresno, California, 93720, United States
NorCal Medical Research, Inc, Greenbrae, California, 94904, United States
Catalina Research Institute, LLC, Montclair, California, 91763, United States
Southern California Dermatology, Inc., Santa Ana, California, 92701, United States
Colorado
New West Physicians Clinical Research, Golden, Colorado, 80401, United States
Connecticut
New England Research Associates, LLC, Bridgeport, Connecticut, 06606, United States
Florida
East Coast Institute for Research, LLC, Jacksonville, Florida, 32204, United States
Georgia
East Coast Institute for Research - Canton, Canton, Georgia, 30114, United States
Rophe Adult and Pediatric Medicine/SKYCRNG, Union City, Georgia, 30291, United States
Illinois
Central Illinois Diabetes and Clinical Research a Division of Prairie Education and Research Cooperative, Springfield, Illinois, 62711, United States
Indiana
Qualmedica Research, LLC, Evansville, Indiana, 47715, United States
Iowa
Iowa Diabetes and Endocrinology Research Center, West Des Moines, Iowa, 50265, United States
Kentucky
Qualmedica Research, Bowling Green, Kentucky, 42101, United States
Maryland
MedStar Health Research Institute (MedStar Physician Based Research Network), Hyattsville, Maryland, 20782, United States
Endocrine and Metabolic Consultants, Rockville, Maryland, 20852, United States
Mississippi
SKY Clinical Research Network Group-Quinn, Ridgeland, Mississippi, 39157, United States
Missouri
Clinvest Research LLC, Springfield, Missouri, 65807, United States
New York
Clarity Clinical Research, East Syracuse, New York, 13057, United States
Great Lakes Medical Research, LLC, Westfield, New York, 14787, United States
North Carolina
Monroe Biomedical Research, Monroe, North Carolina, 28112, United States
Lucas Research, Inc, Morehead City, North Carolina, 28557, United States
Oklahoma
Intend Research, LLC, Norman, Oklahoma, 73069, United States
Pennsylvania
Jefferson Clinical Research Institute (JCRI), Philadelphia, Pennsylvania, 19114, United States
South Carolina
Tribe Clinical Research, LLC, Greenville, South Carolina, 29607, United States
Texas
Dallas Diabetes Research Center, Dallas, Texas, 75230, United States
Juno Research, Houston, Texas, 77040, United States
Southern Endocrinology Associates, Mesquite, Texas, 75149, United States
North Hills Family Medicine/North Hills Medical Research, North Richland Hills, Texas, 76180, United States
Washington
Multicare Institute for Research and Innovation, Spokane, Washington, 99202, United States
Espírito Santo
CEDOES, Vitória, Espírito Santo, 29055450, Brazil
Paraná
Cline Research Center, Curitiba, Paraná, 80030-480, Brazil
São Paulo
Centro de Pesquisa Sao Lucas, Campinas, São Paulo, 13034-685, Brazil
Hospital São Lucas de Copacabana, Rio de Janeiro, 22061-080, Brazil
CPQuali Pesquisa Clínica, São Paulo, 01228-000, Brazil
CPCLIN, São Paulo, 01228-200, Brazil
CEPIC - Centro Paulista de Investigação Clínica, São Paulo, 04266-010, Brazil
Ontario
LMC Diabetes & Endocrinology, Brampton, Ontario, L6S 0C6, Canada
Aggarwal and Associates Limited, Brampton, Ontario, L6T 0G1, Canada
LMC Manna Research, Ottawa, Ontario, K2J 0V2, Canada
Bluewater Clinical Research Group Inc., Sarnia, Ontario, N7T 4X3, Canada
Centricity Research Etobicoke Endocrinology, Toronto, Ontario, M9R 4E1, Canada
Fadia El Boreky Medicine, Waterloo, Ontario, N2J 1C4, Canada
Quebec
9109-0126 Quebec Inc., Montreal, Quebec, H4N 2W2, Canada
Beijing Municipality
Beijing Pinggu District Hospital, Beijing, Beijing Municipality, 101200, China
Chongqing Municipality
Chongqing General Hospital, Chongqing, Chongqing Municipality, 400014, China
Hebei
Hebei Medical University - Harrison International Peace Hospital, Hengshui Shi, Hebei, 053000, China
Heilongjiang
The First Hospital of Harbin Medical University, Harbin, Heilongjiang, 150001, China
The Fourth Hospital of Harbin Medical University, Harbin, Heilongjiang, 150001, China
Henan
The First Affiliated Hospital of Henan University of Science &Technology, Luoyang Shi, Henan, 471003, China
The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450014, China
Hunan
The Second Xiangya Hospital of Central South University, Changsha, Hunan, 410011, China
The First People's Hospital of Yueyang, Yueyang, Hunan, 414000, China
Jiangsu
Changzhou No.2 People's Hospital, Changzhou, Jiangsu, 213164, China
The Second Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, 210011, China
Nanjing First Hospital, Nanjing, Jiangsu, 210012, China
Nanjing Medical University - Nanjing Jiangning Hospital, Nanjing, Jiangsu, 211100, China
The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, 215006, China
Wuxi People's Hospital, Wuxi, Jiangsu, 214023, China
The Affiliated Jiangyin Hospital of Southeast University Medical College, Wuxi, Jiangsu, 214400, China
Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu, 212000, China
Jiangxi
The Third Hospital of Nanchang, Nanchang, Jiangxi, 330009, China
Shandong
Jinan Central Hospital, Jinan, Shandong, 250013, China
Shanghai Municipality
Shanghai Putuo District Center Hospital, Shanghai, Shanghai Municipality, 200062, China
Sichuan
West China Hospital of Sichuan University, Chengdu, Sichuan, 610041, China
Chengdu Fifth People's Hospital, Chengdu, Sichuan, 611130, China
Tianjin Municipality
Tianjin Medical University General Hospital, Tianjin, Tianjin Municipality, 300052, China
Tianjin Medical University Zhu Xianyi Memorial Hospital, Tianjin, Tianjin Municipality, 300070, China
Zhejiang
Zhejiang Hospital, Hangzhou, Zhejiang, 310013, China
Ningbo First Hospital, Ningbo, Zhejiang, 315010, China
Chrudim
INTENDIA klinika s.r.o., Chrudim III, Chrudim, 537 01, Czechia
Jihočeský kraj
MUDr. Alena Vachova, České Budějovice, Jihočeský kraj, 37011, Czechia
Moravskoslezský kraj
MUDr. Tomas Edelsberger, Krnov, Moravskoslezský kraj, 79401, Czechia
Pardubice
Diahelp s.r.o, Pardubice V, Pardubice, 530 02, Czechia
Praha 4
Milan Kvapil s.r.o., Diabetologicka ambulance, Prague, Praha 4, 14900, Czechia
Praha-vých
Diacentrum Brandys n.L. s.r.o., Brandýs nad Labem, Praha-vých, 25001, Czechia
Rychnov Nad Kněžnou
MUDr. Tomas Hrdina, Opočno, Rychnov Nad Kněžnou, 517 73, Czechia
Baden-Wurttemberg
Praxis Sauter & Sauter & Vorbach, Wangen, Baden-Wurttemberg, 88239, Germany
North Rhine-Westphalia
InnoDiab Forschung Gmbh, Essen, North Rhine-Westphalia, 45136, Germany
Medizentrum Essen Borbeck, Essen, North Rhine-Westphalia, 45355, Germany
Rhineland-Palatinate
Diabetologikum Ludwigshafen/Die Praxis am Ludwigsplatz, Ludwigshafen am Rhein, Rhineland-Palatinate, 67059, Germany
Saarland
Zentrum für klinische Studien, Saint Ingbert, Saarland, 66386, Germany
Saxony
Universitaetsklinikum Carl Gustav Carus Dresden, Dresden, Saxony, 01307, Germany
Schleswig-Holstein
RED-Institut GmbH, Oldenburg in Holstein, Schleswig-Holstein, 23758, Germany
Diabeteszentrum Hamburg West, Hamburg, 22607, Germany
Attikí (Region)
Iatriko Paleou Falirou Medical Center, Palaió Fáliro, Attikí (Region), 17562, Greece
Attikí
Alexandra Hospital, Athens, Attikí, 11528, Greece
Thessaloníki
Thermi Clinic, Thessaloniki, Thessaloníki, 570 01, Greece
Athens Euroclinic, Athens, 115 21, Greece
Aichi-ken
Tosaki Clinic for Diabetes and Endocrinology, Nagoya, Aichi-ken, 468-0009, Japan
Chiba
Kashiwa City Hospital, Kashiwa, Chiba, 277-0825, Japan
Tokuyama Clinic, Mihama-ku,Chiba City, Chiba, 261-0004, Japan
Hiroshima
Nippon Kokan Fukuyama Hospital, Fukuyama-shi, Hiroshima, 721-0927, Japan
Hokkaido
Hasegawa Medical Clinic, Chitose, Hokkaido, 066-0032, Japan
Manda Memorial Hospital, Sapporo, Hokkaido, 060-0062, Japan
Ibaraki
MinamiAkatsukaClinic, Mito, Ibaraki, 311-4153, Japan
Nakakinen clinic, Naka, Ibaraki, 311-0113, Japan
Kanagawa
Hayashi Diabetes Internal Medicine Clinic, Chigasaki, Kanagawa, 253-0044, Japan
Medical Corporation Yuga Tsuruma Kaneshiro Diabetes Clinic, Yamato-shi, Kanagawa, 242-0004, Japan
Saitama
Shimizu Clinic Fusa, Saitama-shi, Saitama, 336-0967, Japan
Tokyo
Kumanomae Nishimura Clinic, Arakawa-ku, Tokyo, 116-0012, Japan
Fukuwa Clinic, Chuo-ku, Tokyo, 104-0031, Japan
Hachioji Diabetes Clinic, Hachioji-shi, Tokyo, 192-0083, Japan
Medical Corporation Sato Medical clinic, Ootaku, Tokyo, 143-0015, Japan
Tomonaga Clinic, Shinjuku, Tokyo, 160-0022, Japan
Yoshimura Clinic, Kumamoto, 861-8039, Japan
Abe Clinic, Ōita, 870-0039, Japan
Investigacion En Salud Y Metabolismo Sc, Chihuahua City, 31217, Mexico
Centro de Endocrinologia y Nutricion, Caguas, 00725, Puerto Rico
Private Practice - Dr. Paola Mansilla-Letelier, Guaynabo, 00970, Puerto Rico
Kang-won-do
Kangwon National University Hospital, Chuncheon, Kang-won-do, 24289, South Korea
Kyǒnggi-do
Hanyang University Guri Hospital, Guri-si, Kyǒnggi-do, 11923, South Korea
Seoul-teuk
Severance Hospital, Yonsei University Health System, Seoul, Seoul-teuk, 03722, South Korea